A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)

CompletedOBSERVATIONAL
Enrollment

1,002

Participants

Timeline

Start Date

April 21, 2021

Primary Completion Date

November 11, 2022

Study Completion Date

November 11, 2022

Conditions
Alzheimer DiseaseAlzheimer Disease, Early OnsetMild Cognitive ImpairmentMemory LossMemory DisordersMemory Impairment
Interventions
OTHER

Biomarker Data Collection

During this study, a sample of your blood will be collected and you will have a PET scan taken of your brain. Blood sample results will be compared to PET scan pictures to understand how well the markers in the blood predict whether there is amyloid in the brain. Blood samples will also be collected that contain your genes. These genetic samples will also be compared to PET scans to help researchers understand how different people react to medicines and to understand the genetic causes of Alzheimer's disease. Some of the samples will be stored for future analysis.

Trial Locations (16)

13057

Velocity Clinical Research - Syracuse, Syracuse

32127

Progressive Medical Research, Port Orange

32159

Charter Research - Lady Lake, Lady Lake

32751

ClinCloud, Maitland

K2, Orlando

32792

Charter Research - Winter Park, Winter Park

33026

Visionary Investigators Network - Pembroke Pines, Pembroke Pines

33133

Visionary Investigators Network - Coral Gables, Coral Gables

33176

Visionary Investigators Network - South Miami, Miami

33180

Visionary Investigators Network - Aventura, Aventura

33462

JEM, Lake Worth

33609

Axiom Clinical Research of Florida, Tampa

60640

Great Lakes Clinical Trials, Chicago

66160

Kansas University Alzheimer's Disease Center (KUADC), Fairway

75231

Kerwin Research Center, Dallas

78582

El Faro Health and Therapeutics, Rio Grande City

Sponsors
All Listed Sponsors
lead

GAP Innovations, PBC

INDUSTRY